Circulating Adipokine Levels in Nonobese Women With Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis
Authors:
Open Access
- 7 January 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 11
Abstract
Levels of circulating adipokines in nonobese polycystic ovary syndrome (PCOS) patients have been reported in many studies. However, the results are inconsistent. The aim of this meta-analysis is to assess whether the levels of circulating adipokines are changed in nonobese PCOS relative to nonobese healthy controls. To identify eligible studies, a literature research was performed in the PubMed, Embase, and Web of Science databases without restricting by region, journal, or language. A total of 81 studies met the eligibility criteria. The meta-analysis showed that the circulating level of adiponectin (standardized mean difference [SMD]: -0.95; 95% CI: -1.36 to -0.53) was significantly decreased in nonobese PCOS patients. In contrast, the circulating levels of chemerin (SMD: 1.13; 95% CI: 0.08 to 2.18), leptin (SMD: 0.47; 95% CI: 0.13 to 0.81), resistin (SMD: 0.45; 95% CI: 0.03 to 0.88), and visfatin (SMD: 1.38; 95% CI: 0.68 to 2.09) were significantly increased in nonobese PCOS patients. There were no significant changes in the circulating levels of apelin (SMD: 0.32; 95% CI: -1.34 to 1.99), irisin (SMD: 1.01; 95% CI: -0.68 to 2.70), omentin (SMD: -0.37; 95% CI: -1.05 to 0.31), or vaspin (SMD: 0.09; 95% CI: -0.14 to 0.32). Thus, scientific evidence suggests that the circulating adipokine levels are altered in nonobese PCOS patients compared to nonobese healthy controls. Therefore, independent of the degree of obesity, dysregulated circulating adipokine levels might play important roles in the occurrence and development of PCOS.Keywords
All Related Versions
Funding Information
- Wenzhou Municipal Science and Technology Bureau (Y20180271)
This publication has 51 references indexed in Scilit:
- Epidemiology, diagnosis, and management of polycystic ovary syndromeClinical Epidemiology, 2013
- Deletion of the Androgen Receptor in Adipose Tissue in Male Mice Elevates Retinol Binding Protein 4 and Reveals Independent Effects on Visceral Fat Mass and on Glucose HomeostasisDiabetes, 2012
- ChemR23 Dampens Lung Inflammation and Enhances Anti-viral Immunity in a Mouse Model of Acute Viral PneumoniaPLOS Pathogens, 2011
- Chemerin and its receptors in leukocyte trafficking, inflammation and metabolismCytokine & Growth Factor Reviews, 2011
- Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese menJournal of Sports Sciences, 2010
- Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndromeGynecological Endocrinology, 2009
- Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin actionAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Effect of Adiponectin Gene Polymorphisms on Circulating Adiponectin and Insulin Resistance Indexes in Women with Polycystic Ovary SyndromeClinical Chemistry, 2005
- Leptin selectively decreases visceral adiposity and enhances insulin action.Journal of Clinical Investigation, 1997
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986